Tom Doherty
@tdoherty.bsky.social
AD Clinical development scientist working in industry. Views are my own. #NUFC
This work further demonstrates the utility of ptau217R for disease stage assessment, patient screening and monitoring, in clinical trials and clinical practice.
It also builds on our prior work on predicting amyloid values across the AD continuum alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
It also builds on our prior work on predicting amyloid values across the AD continuum alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease
BACKGROUND This study investigated the potential of phosphorylated plasma Tau217 ratio (pTau217R) and plasma amyloid beta (Aβ) 42/Aβ40 in predicting brain amyloid levels measured by positron emissio...
alz-journals.onlinelibrary.wiley.com
November 24, 2024 at 9:31 AM
This work further demonstrates the utility of ptau217R for disease stage assessment, patient screening and monitoring, in clinical trials and clinical practice.
It also builds on our prior work on predicting amyloid values across the AD continuum alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
It also builds on our prior work on predicting amyloid values across the AD continuum alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
This research demonstrates the ability to also reliably predict tau levels simultaneously across Braak stages and multiple brain regions via a single, unified model. Notably, a pTau217R-based algorithm could lower the need for tau PET scans by up to 65% while maintaining 95% sensitivity.
November 24, 2024 at 9:31 AM
This research demonstrates the ability to also reliably predict tau levels simultaneously across Braak stages and multiple brain regions via a single, unified model. Notably, a pTau217R-based algorithm could lower the need for tau PET scans by up to 65% while maintaining 95% sensitivity.